"Epitranscriptomics: RNA Modifications and Their Biological Roles"

Introduction

For decades, DNA modifications (like DNA methylation) dominated discussions of epigenetics. But now, scientists are uncovering a new regulatory layer: Epitranscriptomics — the study of chemical modifications on RNA.

More than 170 different chemical modifications have been identified on RNAs. These modifications fine-tune RNA stability, localization, translation, and interactions, influencing health and disease.

The most well-studied is N6-methyladenosine (m6A), often called the “epigenetic mark on RNA.”


1. Key RNA Modifications

a) m6A (N6-Methyladenosine)

  • Most abundant internal mRNA modification.

  • Added by “writers”: METTL3/METTL14 complex.

  • Removed by “erasers”: FTO, ALKBH5.

  • Recognized by “readers”: YTH domain proteins.

  • Functions: regulates splicing, stability, translation efficiency.

b) m5C (5-Methylcytosine)

  • Found in tRNA, rRNA, mRNA.

  • Linked to RNA stability and translation fidelity.

c) Pseudouridine (Ψ)

  • Isomer of uridine.

  • Enhances RNA folding, stability, and translation accuracy.

d) A-to-I Editing (Adenosine-to-Inosine)

  • Carried out by ADAR enzymes.

  • Changes coding potential and regulates immune responses.

e) Other Modifications

  • m1A, hm5C, Queuosine, etc.

  • Often found in tRNA and rRNA, ensuring proper protein synthesis.


2. Biological Functions of RNA Modifications

  • RNA Splicing – m6A influences exon selection.

  • mRNA Stability – modified RNAs degrade faster or slower depending on the mark.

  • Translation Control – m6A and Ψ regulate ribosome recruitment.

  • Stress Response – modified RNAs adapt translation under stress.

  • Immune Regulation – A-to-I editing prevents autoimmune reactions.


3. Epitranscriptomics in Disease

a) Cancer

  • Overactive m6A writers/readers → uncontrolled proliferation.

  • Example: METTL3 upregulation drives acute myeloid leukemia (AML).

b) Neurological Disorders

  • m6A dysregulation implicated in learning, memory, and psychiatric diseases.

  • ADAR malfunction → Aicardi-Goutières syndrome (autoimmunity).

c) Viral Infections

  • Viruses hijack host RNA modifications.

  • Example: HIV and influenza RNAs are m6A-modified → aid viral replication.

d) Metabolic Diseases

  • FTO, an m6A eraser, linked to obesity and diabetes.


4. Epitranscriptomics as a Therapeutic Target

  • Inhibitors of m6A enzymes being explored for cancer therapy.

  • Engineered RNA with modified bases (Ψ, m5C) improves RNA drug stability (used in mRNA vaccines like Pfizer-BioNTech & Moderna COVID-19).

  • RNA editing therapies (targeting ADAR enzymes) → potential for fixing genetic diseases.

6. Future Directions

  • Epitranscriptome profiling: New sequencing technologies to map modifications at single-nucleotide resolution.

  • RNA modification drugs: Small molecules to correct dysregulated RNA modifications.

  • Precision RNA editing: Combining CRISPR with ADARs to rewrite RNA.

  • RNA vaccines 2.0: Using optimized modifications for long-term stability.


# Conclusion

Epitranscriptomics reveals that RNA is not just a passive messenger, but a dynamic molecule with chemical complexity.

By decoding these RNA marks, we can better understand gene regulation, disease mechanisms, and therapeutic opportunities. In the near future, RNA modifications may become as important in medicine as DNA mutations and epigenetic changes

Comments

Popular posts from this blog

Exploring the Power of PCR and DNA Isolation

3D Bioprinting – Printing Organs, One Layer at a Time

Scientific Discoveries of 2025: A Year of Breakthroughs That Could Change the World